Key View: Vietnam's pharmaceutical market will see substantial growth over the long term as the country continues to improve access to healthcare and medicines through the implementation of its national health insurance scheme. Vietnam offers considerable longer-term commercial opportunities for a range of pharmaceutical players. Its large population number and authorities' support for pharmaceutical investment are just some of the factors that would provide a fertile ground for substantial volume and value growth. However, this potential will mostly attract generic drug companies, given the low pharmaceutical spending and regulatory regime risks. In addition, the Covid-19 outbreak will pose significant hurdles to universal healthcare achievement, as well as both the pharmaceuticals and healthcare sector, as the spread continues.
Table of Contents
- Key View
- Vietnam Pharmaceuticals Covid-19 Impact
- SWOT
- Industry Forecast
- Pharmaceutical Market Forecast
- Healthcare Market Forecast
- Prescription Drug Market Forecast
- Patented Drug Market Forecast
- Generic Drug Market Forecast
- OTC Medicine Market Forecast
- Pharmaceutical Trade Market Forecast
- Industry Risk/Reward Index
- Asia Pacific Innovative Pharmaceuticals Risk/Reward Index
- Vietnam Innovative Pharmaceuticals Risk/Reward Index
- Regulatory Development
- Regulatory Review
- Market Overview
Competitive Landscape
- Company Profile
- DHG Pharmaceutical
- GlaxoSmithKline
- Sanofi
- Traphaco
- Vietnam Pharmaceutical Corporation
- Vietnam Demographic Outlook
- Pharmaceuticals & Healthcare Glossary
- Pharmaceuticals & Healthcare Methodology
